2nd Quarter - Report

PRIME THERAPEUTICS for PRIME THERAPEUTICS

Firm
Client
Income
—
Expenses
$190,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

S. 867: The Medicare Prescription Drug Program Integrity and Transparency Act of 2013 2014 Final Call Letter Medicare Part D (Preferred pharmacy networks, auto refill through mail service pharmacies) S.117 Medicare Prescription Drug Price Negotiation Act of 2013

LobbyistCovered position, as disclosed
STACEY FAHRNER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS)

Bills named: S. 117 (113th), S. 867 (113th)

Pharmacy PHA

S. 867: The Medicare Prescription Drug Program Integrity and Transparency Act of 2013 2014 Final Call Letter Medicare Part D (Preferred pharmacy networks, auto refill through mail service pharmacies) S.117 Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 1188: Preserving Our Hometown Independent Pharmacies Act of 2013

LobbyistCovered position, as disclosed
STACEY FAHRNER —

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE

Bills named: S. 117 (113th), H.R. 1188 (113th), S. 867 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.